![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The Third Annual T-cell Lymphoma Forum, held on 27–29 January 2011 in San Francisco (CA, USA), continued in the spirit of the two earlier conferences and provided a collegial venue for clinicians and scientists to discuss advances in the science and treatment of T-cell lymphomas. More than 40 experts from around the world presented updates on classification, epidemiology and prognosis; rare and T-cell lymphomas of unspecified origin, CD30+ T-cell lymphomas; new treatment strategies; new agents and rational combinations; and transplantation. Of particular interest this year was a discussion on the link between breast implants and anaplastic large-cell lymphoma, which coincided with the US FDA announcement of this rare but noteworthy relationship. Submitted abstracts and poster presentations rounded off each of the sessions.
Financial & competing interests disclosure
Kensei Tobinai has received grant/research funding from Celgene, Kyowa Hakko Kirin, Merck, Mundipharma, Novartis and Pfizer. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Kensei Tobinai acknowledges the support of Erilyn B Riley, Hemedicus, Inc., for writing assistance, funded by Jonathan Wood & Associates.